Philip R. Tempest

737 total citations
18 papers, 560 citations indexed

About

Philip R. Tempest is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Philip R. Tempest has authored 18 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Immunology. Recurrent topics in Philip R. Tempest's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (6 papers) and Protein purification and stability (3 papers). Philip R. Tempest is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (6 papers) and Protein purification and stability (3 papers). Philip R. Tempest collaborates with scholars based in United Kingdom and United States. Philip R. Tempest's co-authors include Tristan J. Vaughan, Jane Osbourn, William J. Harris, Frank J. Carr, Geraldine Taylor, Bevan Moseley, P. Brookes, Julie Furze, Colin S. Cooper and Christopher S. Cooper and has published in prestigious journals such as The EMBO Journal, Nature Biotechnology and The Journal of Immunology.

In The Last Decade

Philip R. Tempest

18 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip R. Tempest United Kingdom 12 363 285 111 93 65 18 560
Paul Sims United States 10 317 0.9× 213 0.7× 247 2.2× 105 1.1× 65 1.0× 14 762
Piet J. Boender Netherlands 14 330 0.9× 200 0.7× 65 0.6× 87 0.9× 84 1.3× 24 582
Benedikte Serruys Belgium 7 188 0.5× 207 0.7× 120 1.1× 76 0.8× 28 0.4× 10 367
Laurie May United States 5 264 0.7× 203 0.7× 378 3.4× 168 1.8× 29 0.4× 7 734
Johan Lantto United States 17 341 0.9× 392 1.4× 217 2.0× 314 3.4× 48 0.7× 38 804
J. Bagley United States 11 193 0.5× 150 0.5× 161 1.5× 55 0.6× 15 0.2× 15 465
Georges Orfanoudakis France 16 323 0.9× 115 0.4× 101 0.9× 125 1.3× 47 0.7× 27 605
Sang Jick Kim South Korea 12 284 0.8× 191 0.7× 104 0.9× 91 1.0× 15 0.2× 24 444
Rajesh Vij United States 10 365 1.0× 140 0.5× 104 0.9× 265 2.8× 26 0.4× 13 726
Koen Wagner Netherlands 16 219 0.6× 188 0.7× 186 1.7× 115 1.2× 37 0.6× 21 626

Countries citing papers authored by Philip R. Tempest

Since Specialization
Citations

This map shows the geographic impact of Philip R. Tempest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip R. Tempest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip R. Tempest more than expected).

Fields of papers citing papers by Philip R. Tempest

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip R. Tempest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip R. Tempest. The network helps show where Philip R. Tempest may publish in the future.

Co-authorship network of co-authors of Philip R. Tempest

This figure shows the co-authorship network connecting the top 25 collaborators of Philip R. Tempest. A scholar is included among the top collaborators of Philip R. Tempest based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip R. Tempest. Philip R. Tempest is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Howard, Chris, et al.. (1999). Depletion of bovine CD8+ T cells with chCC63, a chimaeric mouse-bovine antibody. Veterinary Immunology and Immunopathology. 71(3-4). 215–231. 8 indexed citations
2.
Vaughan, Tristan J., Andrew J Williams, Jane Wilton, et al.. (1999). A fully human antibody neutralising biologically active human TGFβ2 for use in therapy. Journal of Immunological Methods. 227(1-2). 17–29. 34 indexed citations
3.
Vaughan, Tristan J., Jane Osbourn, & Philip R. Tempest. (1998). Human antibodies by design. Nature Biotechnology. 16(6). 535–539. 117 indexed citations
4.
Graziano, R F, Philip R. Tempest, Piran C. L. White, et al.. (1995). Construction and characterization of a humanized anti-γ-Ig receptor type I (Fc γ RI) monoclonal antibody. The Journal of Immunology. 155(10). 4996–5002. 57 indexed citations
5.
Tempest, Philip R., et al.. (1995). Identification of framework residues required to restore antigen binding during reshaping of a monoclonal antibody against the glycoprotein gB of human cytomegalovirus. International Journal of Biological Macromolecules. 17(1). 37–42. 16 indexed citations
6.
Dillon, Susan B., John J. Trill, Tony Hart, et al.. (1995). Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Biochemical Society Transactions. 23(4). 1063–1067. 5 indexed citations
7.
8.
Tempest, Philip R., Patricia M. White, E. Diane Williamson, et al.. (1994). Efficient generation of a reshaped human mAb specific for the α toxin of Clostridium perfringens. Protein Engineering Design and Selection. 7(12). 1501–1507. 3 indexed citations
9.
Armour, Kathryn L., et al.. (1994). Sequences of heavy and light chain variable regions from four bovine immunoglobulins. Molecular Immunology. 31(17). 1369–1372. 13 indexed citations
10.
Corti, Angelo, et al.. (1994). Idiotope determining regions of a mouse monoclonal antibody and its humanized versions. Journal of Molecular Biology. 235(1). 53–60. 8 indexed citations
11.
Armour, Kathryn L., William J. Harris, & Philip R. Tempest. (1993). Cloning and expression in Escherichia coli of the cDNA encoding human cardiac troponin I. Gene. 131(2). 287–292. 7 indexed citations
12.
Tempest, Philip R., et al.. (1991). Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo. Nature Biotechnology. 9(3). 266–271. 126 indexed citations
13.
Chan, Andrew M., et al.. (1987). Primary structure of the met protein tyrosine kinase domain.. PubMed. 1(2). 229–33. 24 indexed citations
14.
Tempest, Philip R., et al.. (1986). Activation of the met oncogene in the human MNNG-HOS cell line involves a chromosomal rearrangement. Carcinogenesis. 7(12). 2051–2057. 20 indexed citations
15.
Tempest, Philip R., Colin S. Cooper, & Glenn N. Major. (1986). The activated human met gene encodes a protein tyrosine kinase. FEBS Letters. 209(2). 357–361. 29 indexed citations
16.
Cooper, Christopher S., et al.. (1986). Amplification and overexpression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts.. The EMBO Journal. 5(10). 2623–2628. 54 indexed citations
17.
Tempest, Philip R. & Bevan Moseley. (1982). Lack of ultraviolet mutagenesis in radiation-resistant bacteria. Mutation Research Letters. 104(4-5). 275–280. 16 indexed citations
18.
Tempest, Philip R. & Bevan Moseley. (1980). Defective excision repair in a mutant of Micrococcus radiodurans hypermutable by some monofunctional alkylating agents. Molecular and General Genetics MGG. 179(1). 191–199. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026